The main driver in paediatric clinical research is ethics. All other and subsequent aspects will depend on keeping this obligation at the highest possible and acceptable level of quality. Indeed, research is necessary in children in order to improve their health, whereas the past situation, where such investigations were deemed not feasible or to be avoided at any cost can no longer be considered ethical. Children have the right to benefit from the improvement in therapy and diagnostic tools, whilst it is well-known nowadays that deriving doses and dosing schedules using rough methodologies (linear extrapolations based on body weight or surface) does not hold true, and may expose them to risky or inefficient treatments. Children at various ages are exposed to different risk-benefit ratios. These variables can only be defined if a better knowledge of both the dangers and the advantages of the drugs are assessed. It also has to be recognised that such characteristics can be perceived differently across cultural backgrounds in Europe. These divergences should be smoothened or even erased on the basis of the principle of equality in the European Union, indicating the need for further discussion aimed at achieving harmonisation. We may still be far from this ideal goal, but the next step (see the article by Altavilla) should strive to lead to European ethical recommendations, facilitating the work of researchers for the benefit of the paediatric population as a whole.
Concomitantly, researchers should make an effort to simplify studies performed in children by limiting sampling and related pain, by reducing the burden and psychological stress for the patients, whilst probably increasing the sophistication of the methodologies used in these investigations. This approach implies developing methodological research, being innovative in that field, and continuously testing and validating. It is obvious that children are not just small adults, because growth is not a linear variable. The role of population pharmacokinetic-pharmacodynamic (PK-PD) modelling using a non-linear mixed effect (see the article by Danhof et al.) should be emphasised as a tool to confirm rational, patient-tailored dosing schemes. Indeed, absorption, distribution, metabolism and excretion of a medicinal product may all differ to varying degrees in adults and children, confirming the need for PK data in these younger age groups. The task is rendered even more difficult because of the need to limit the blood sample volumes, which implies that validated techniques for microanalyses need to be developed. The development of a model means first developing suitable methodology to create such constructs. These are by nature always "wrong", but useful; indeed, if internally validated and externally confirmed (using similar sets of data found in the published literature or creating new datasets by splitting an adequate initial sample size), such models need to demonstrate their reliability in prospective clinical trials. However, the exercise implies the need for a proper design, requiring its power calculation and leading hopefully to a final validation. In the case of a positive outcome, a future cross validation of the model can be further considered, in which the parameters of influence defined in the PK-PD model (and these might not only be age, gender, body weight or surface, but also liver size, lung capacity or seated height, for example) can be applied and evaluated in a similar drug belonging to the same class, for instance, or sharing the same metabolism or mechanism of action.
In this latter context, the genetic background of the patient may play a role, sometimes an important one.
Acknowledging that the genetic expression (phenotype) evidently starts to act from birth suggests that the fields of pharmaco-genetics/genomics should have pushed the interest of researchers of the paediatric age range ahead or in parallel with the adult investigations. This has obviously not been the case so far (see the article by Russo et al.). Again, in terms of PK-PD, the variability of drug response does not only happen to be a consequence of the genetic polymorphism, but also of the maturation of the generelated phenotype expression. Thus, rather than observing the variability in exposures or responses, the identification and understanding of the genetic inheritance could contribute to predicting part of the drug response and anticipating some individual potential toxicity. Although promising, this field has yet to be explored and the data that are available have so far been underused, with only a few exceptions.
Similarly, the standard use of double-blind randomised controlled trials (RCTs) can be challenged in some circumstances. Whilst acknowledging their incomparable value in assessing efficacy under ideal circumstances to limit bias or external influences, such designs are often limited in terms of sample size and duration, particularly in children when the comparator is placebo, which hampers a sound safety assessment. Pharmaco-epidemiology is an option to fill the gap, bridging the contribution of each; indeed, whereas the RCTs assess efficacy under stringent if not somewhat artificial conditions, effectiveness and long-term safety can be monitored in the field using a range of study designs: case reports or series mainly delivering signals, cross-sectional studies exploring links (but not causality) between exposure and disease, retrospective/prospective cohort studies to estimate incidences rates, particularly of supposed risk(s), (nested) case-control studies etc. (see the article by Verhamme et al.) . Clearly these approaches are not limited to children; on the contrary, they are of high interest in this age group where both overall exposure of a drug is low and the incidence of (specific) adverse events is often lower than in adults. The extension of safety databases, the last and recent EU legal provisions implemented during the last decade allow us to expect that automated databases will produce along reasonable timelines more accurate and reliable data on the safe use of drugs in children. These databases are not only collected by health care providers, but some are also managed within the EU regulatory system. Their size is supposed to enable the detection of rare events occurring after long periods of exposure or after remote exposure. This is particularly important for generating signals and evidence in children or adolescents who have been exposed to medicinal products during pregnancy or infancy. Currently, the data-mining is underexploited and research projects inadequate. However, it can be expected that by the time the information is properly standardised, new tools to conduct research will have emerged that need validation, but the door to interesting perspectives will probably be opened, particularly in paediatric pharmaco-vigilance.
Indeed, one could imagine following the expression of the gene profiles from birth onwards. In any case, blood sampling at a very young age is a challenge, as exemplified by the reluctance of parents and families to let clinical trials be conducted in their newborn children, even if they are sick (see the paper by Ligi et al.). The specificities of neonatal development linked to maturation (particularly in preterms) concern all organs, but in particular in the current context those involved in drug handling: skin, lungs or the digestive tract mainly for absorption; heart function, residual fetal circulation and fluid compartments for distribution; the liver for metabolism; and the kidney and GI tract for elimination should be looked at differently from those exposed to toxicity, like the brain and the acoustic nerve or the immune system, taking into consideration on top of this some intercurrent disease (sepsis, glucose instability etc.). Further readjustment of several components of multi-drug therapy takes place not only because of an ongoing maturation process, but also following the evolution of the clinical condition, both being closely interrelated. The main issue is probably the experience of the investigator, of the team and of the institution as a whole, which are closely supported by a safety monitoring board. In any case, major difficulties remain in terms of the heterogeneity of small samples and the need to call upon less classical statistical methods using active comparators in the design and relying mostly on add-on treatment compared head-to-head with standard of care.
One of the key issues relates to the fact that the standard of care is not always as standard as one would wish, leading to strict endpoints having to be defined and requiring multicentre clinical trials to enroll sufficient patients due to the rarity of the disease. However, most of the common endpoints used in the design of trials have been validated in adults, but rarely in children and if ever in neonates.
One of the most tempting approaches in paediatric designs, namely the option to study different dosing regimens in different combinations at variable time points, adding interim analyses that often use different endpoints still to be validated in (age) subgroups, leads to multiplicity interferences.
In paediatric oncology it might be less often the case. Indeed, the number of studies is limited, as are their sizes. In any case, hard endpoints, like time-to-death, are impossible to achieve, whereas the cure rate remains the most relevant endpoint (see the article by Paolo Paolucci), whilst other parameters, like quality of life, are poorly explored. Similarly, the long-term monitoring of survival is currently not realistically attainable, indicating the need to invest (e.g. the creation of registries etc.) and improve in the field (e.g. coordinate research efforts etc,).
The overall preferences of regulators for the evaluation of (new) medicinal products are well illustrated when grading the usual outcome measures in the field of respiratory diseases. Objective endpoints, like lung function (FEV1, peak flow etc.), are considered the more robust markers of surrogacy followed by less preferred subjective measures, like symptom scores or quality of life measurement. Health-related outcomes, like a reduction in the need for drugs or for hospitalisations and better compliance with therapy, are surely also well considered and supportive as long as they are of real clinical relevance for the patients and not only targeting health economics (see the article by de Benedictis et al.). In the end, it remains paramount to reconcile any surrogate endpoint (objective or subjective) with its clinical relevance to ascertaining the use of meaningful and convincing outcome measures, reflecting tangible benefits for the patients. Surprisingly, the most common and severe respiratory diseases (asthma and cystic fibrosis respectively) still lack wellaccepted and robust surrogates to demonstrate in a workable manner beneficial long-term effects for the former or the eradication of lung colonisation for the latter.
The use of composite endpoints can represent a way of trying to address problems that are still unresolved. This approach has been successful in the field of paediatric rheumatic disease (see the article by Ruperto et al.) . The heterogeneity of the clinical manifestations and the development of a wide range of novel medicinal products suggest that investigating the response to therapy (improvement, stabilisation, remission etc.) might be the most important if not the sole outcome measure. Using a strict methodology (first collect a set of candidate measures defined using the Delphi technique, then gather large-scale data for an evidence-based evaluation of the candidate measures, conduct a final validation of the best performers), different domains (physician's assessment of disease activity, parent's global assessment, quality of life) were identified as the useful components for constructing a composite endpoint enriched by additional measures specific to each disease (juvenile idiopathic arthritis, systemic lupus erythematosus, dermatomyositis).
Addressing the field of subjective symptoms like pain leads to major hurdles when dealing with the age group that is devoid of any or recognisable verbal expression (see the article by Ceelie et al.). To circumvent this difficulty, pain instruments in terms of scores were developed, validated and widely used in postoperative pain evaluation. However, in some instances (e.g. critically ill and intubated ICU patients, cognitively impaired subjects etc.), children cannot vocalise their suffering, whilst pain needs to be assessed. Some new tools (e.g. skin conductance, hormonal stress markers etc.) can contribute and measure pain with more accuracy, also helping to understand better some wide interindividual variations in response to treatment. However, research in this sensitive field is still needed.
Ending with a fully subjective concept, namely "quality of life", the complexity of individual perception is increased by the multiplicity of the items involved and the value attached to them, differing from person to person, from culture to culture, from one social background to another etc. (see the article by Trana). Nonetheless, this dimension is important to capture in children, because with advances in medical care children tend to survive more chronic and more disabling conditions. Furthermore, the child's own perception contributes to helping parents and physicians make decisions. In practice, the burden of disease, the need for hospital admissions, the intrusive procedures and the psychological uncertainties linked to threatening conditions and survival or shortened life expectancy, all have an impact on childhood development. Under such circumstances the inclusion of quality of life measurements contributes to comparisons of interventions and outcomes of studies. Still, measuring quality of life properly remains a challenge, but currently profile scoring systems seem preferable to indexes or total scores. These should be appropriate to the disease concerned and often fine-tuned according to the disease stage (e.g. muscular disorders).
This supplement of European Journal of Clinical Pharmacology is a valid contribution to a number of issues resurgent from, and actualised by, the recent paediatric regulation. The need to update the methodology used to conduct clinical trials in children and the importance of defining validated endpoints as part of this exercise are exemplified in the different articles. Let us hope that researchers, supported by industry, will take up the challenge.
